bluuebunny/crossref_metadata_2025_split huggingface dataset:
Functional benzoxazines containing ammonium salt of carboxylic acid: Synthesis and highly activated thermally induced ring‐opening polymerization
Authors: Sudo Atsushi , Kudoh Ryoichi , Endo Takeshi 
Published: February 2011

Abstract1,3‐Benzoxazine monomers having ammonium salt of carboxylic acid have been developed. These 1,3‐benzoxazines 1a and 1b were easily synthesized from the corresponding tetrabutylammonium salts of glycine and β‐alanine, respectively. The glycine‐derived benzoxazine 1a exhibited remarkably high reactivity, which allowed its thermally induced ring‐opening polymerization in bulk at 100 °C, at which N‐methyl‐1,3‐benzoxazine 1d did not undergo the polymerization at all. © 2011 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem, 2011
Simultaneous in situ measurement of sorption and swelling of polymers in gases and supercritical fluids
Authors: Ruiz‐Alsop Rosa N. , Mueller Philipp A. , Richards John R. , Kao Chien‐Ping Chai , Brown Gary G. 
Published: February 2011

AbstractIn this work, a novel method to simultaneously measure in situ swelling and sorption of gases and supercritical fluids in polymers in a commercially available apparatus is proposed. A gravimetric approach reported recently is applied to measure sorption whereas swelling is determined in situ by direct visualization. The proposed method has been used to study the sorption and swelling of carbon dioxide in poly (methyl methacrylate) and the obtained results are compared to previously published literature data. © 2011 Wiley Periodicals, Inc. J Polym Sci Part B: Polym Phys, 2011
What do 1281 distress screeners tell us about cancer patients in a community cancer center?
Authors: Kendall Jeff , Glaze Kelly , Oakland Shari , Hansen Jeanice , Parry Carla 
Published: February 2011

AbstractObjective: The 2008 Institute of Medicine's Report, Cancer Care for the Whole Patient (IOM, 2008), recommends screening cancer patients for distress. Cancer programs throughout the United States are struggling to achieve this standard. The IOM report indicates that only 14% of 1000 randomly selected American Society of Clinical Oncology (ASCO) members and eight of 15 National Comprehensive Cancer Network (NCCN) centers reported screening for distress in at least some of their patients [J Natl Compr Cancer Netw 2007;5:99–103]. Without adequate screening, distress often goes unnoticed by cancer professionals and there is little information about the prevalence of distress. The main objective of this article is to present data from 1281 distress screenings completed by patients treated within a community cancer center. Specifically, this article reports the intensity of distress, frequency of problem endorsement, and requests for specific psychosocial providers by cancer patients.Method: Medical and radiation oncology patients completed a distress screener before their first physician appointment. The screening instrument included the Distress Thermometer, a symptom checklist, and a list of psychosocial providers that the patient could request to meet.Results: Thirty‐two percent of this sample rated distress above the threshold level. Worry was the most common problem endorsed followed by financial issues. Emotional concerns were endorsed by 59% of the sample. The cancer dietitian was the psychosocial professional most frequently requested by patients.Conclusion: Distress screening can be accomplished within a community cancer center but the provision of psychosocial services is difficult given the high volume of need. Copyright © 2011 John Wiley & Sons, Ltd.
The detection and management of emotional distress in cancer patients: the views of health‐care professionals
Authors: Absolom Kate , Holch Patricia , Pini Simon , Hill Kate , Liu Alan , Sharpe Michael , Richardson Alison , Velikova Galina ,   on behalf of the NCRI COMPASS Supportive and Palliative Care Research Collaborative
Published: February 2011

AbstractObjective: Emotional distress (ED) is an under‐diagnosed problem in cancer patients and over the last decade a number of national guidelines have recommended an assessment and management model based on appropriate health professional response to a hierarchy of patient need. This study explores the views of cancer professionals regarding their current roles and responsibilities in the detection and management of ED, use of screening tools and access to expert psychological support.Methods: Interviews with 23 professionals were conducted [6 clinical nurse specialists (CNS), 8 oncologists, 4 surgeons and 5 ward sisters] from hospitals in Yorkshire, UK. Data were evaluated using framework analysis.Results: Detection of ED was seen to be the responsibility of the whole cancer team though nurses, particularly CNSs, are heavily depended upon to assess and manage distress. Experience of screening tools was limited and a number of reservations were expressed about routine implementation. A wide range of services are used to support distressed patients but a lack of referral guidance and access to specialist psychological care were reported to be a significant barrier to effective management.Conclusions: Cancer professionals describe working within the fundamental principles of the guidance frameworks; however, access to specialist support do not appear to meet recommendations, leaving the CNS with considerable responsibility for the detection and management of ED. Support for ED may be improved by the introduction of routine screening along with appropriate training and implementation of referral guidelines to assist professionals in accessing specialist psychology services. Copyright © 2011 John Wiley & Sons, Ltd.
Cancer Care Ontario's experience with implementation of routine physical and psychological symptom distress screening
Authors: Dudgeon Deborah , King Susan , Howell Doris , Green Esther , Gilbert Julie , Hughes Erin , Lalonde Brendon , Angus Helen , Sawka Carol 
Published: February 2011

AbstractObjective: In late 2006, Cancer Care Ontario launched a quality improvement initiative to implement routine screening with the Edmonton Symptom Assessment System (ESAS) for cancer patients seen in fourteen Regional Cancer Centres throughout the province.Methods: A central team: created a provincial project plan and management and evaluation framework; developed common tools and provided expert coaching and guidance, provincial data analysis, progress reporting and program evaluation. Regional Steering Committees and Improvement teams were accountable for planning and coordination within each region and supported by a funded Regional Improvement Coordinator. A hybrid model for quality improvement facilitated process improvements and uptake of screening.Results: Challenges to implementation included: lack of consensus on the chosen screening tool, lack of guidance for assessment or management of high scores, concern of inadequate time or resources to address issues identified by the screening, data entry was labour intensive, resistance to change and challenges to the traditional care model. Essential components for success were: centralized project management, a person dedicated to implementation of the project locally, clinical champions, clearly identified aims, monthly regional data reporting and implementation of quality improvement methodologies with expectations for performance. To achieve screening aims many centres engaged all members of the team, examined the roles of the different members and reorganized workflow and responsibilities and changed booking times. In March 2010, approximately 25,000 ESAS's were completed in the regional cancer centres across Ontario, with 60% of lung cancer patients and almost 40% of all other cancer patients who visited the Regional Cancer Centres screened.Conclusion: Routine physical and psychological distress screening is possible within regional cancer centres. Although considerable effort and investment is required, it is worthwhile as it helps create a culture that is more patient‐centered. Copyright © 2011 John Wiley & Sons, Ltd.
No improvement in distress and quality of life following psychosocial cancer rehabilitation. A randomised trial
Authors: Rottmann Nina , Dalton Susanne Oksbjerg , Bidstrup Pernille Envold , Würtzen Hanne , Høybye Mette Terp , Ross Lone , Christensen Jane , Frederiksen Kirsten , Hansen Dorte Gilså , Johansen Christoffer 
Published: February 2011

AbstractObjective: Rehabilitation programmes are intended to help cancer patients achieve optimal functioning and live independently. We evaluated whether a psychosocial rehabilitation course was effective in relieving cancer patients' distress and improving their well‐being.Methods: Patients with breast, prostate or colorectal cancer diagnosed within 2 years who had finished primary treatment were randomised to usual care or a 6‐day residential course of lectures, discussions and peer groups on issues related to treatment and living with cancer. Changes in self‐reported distress (POMS‐Sf) and quality of life (EORTC QLQ‐C30) from baseline to 1 and 6 months' follow‐up were measured. Analyses were adjusted for baseline scores of outcome, cancer site, time since diagnosis, gender, age and education.Results: Of 507 patients, 452 were included in the analyses, 404 completed the 1‐month and 394 the 6‐month assessment. Patients in the control group showed greater decreases in total mood disturbance and subscales of the POMS‐Sf and showed more improvement in emotional, cognitive and social functioning at both 1 and 6 months and in role functioning at 6 months than the intervention group. A similar pattern was observed in analyses of breast cancer patients only.Conclusion: A 6‐day residential rehabilitation course did not relieve cancer patients' distress or improve their well‐being. Copyright © 2011 John Wiley & Sons, Ltd.
A Comparison between Gas and Atomized Liquid Precursor States in the Deposition of Functional Coatings by Pin Corona Plasma
Authors: Herbert Peter Anthony Fry , O'Neill Liam , Jaroszyńska‐Wolińska Justyna , Stallard Charlie Patrick , Ramamoorthy Amsarani , Dowling Denis Pius 
Published: February 2011

AbstractThis work directly compares vapour and liquid aerosol states for the deposition of perfluorocarbon coatings using an atmospheric pressure, non‐thermal equilibrium plasma jet system. The objective of the study is to evaluate how the physical state of the precursor (gas or liquid), influences the fragmentation of the monomer molecules in the plasma and the subsequent coating properties. Specifically the effect of gas or liquid aerosol precursor feed on the ability to achieve a soft plasma polymerization (SPP) is assessed with a view to producing a coating that exhibits minimal fragmentation, while being well cross‐linked. The precursor (perfluoro‐1‐decene) was introduced into a helium plasma and coatings deposited at rates of up to 50 nm · min−1. The deposited coatings were examined using XPS, FTIR, contact angle and ellipsometric measurements. These indicated that a controlled polymerization reaction through the vinyl group of the monomer had taken place in the case of the gas deposited samples with only minor fragmentation of the functional perfluoro chain. Furthermore, a high level of cross‐linking was achieved and the perfluorocarbon coatings were stable to a toluene wash. In contrast, while coatings deposited using the liquid deposition technique showed good retention of monomer molecular structure, they exhibited poor stability when immersed in toluene. This is attributed to lower levels of cross‐linking of the liquid precursor in the plasma, compared with coatings deposited using the gaseous precursor technique. magnified image
Increased cancer cell proliferation in prostate cancer patients with high levels of serum folate
Authors: Tomaszewski Jeffrey J. , Cummings Jessica L. , Parwani Anil V. , Dhir Rajiv , Mason Joel B. , Nelson Joel B. , Bacich Dean J. , O'Keefe Denise S. 
Published: February 2011

AbstractBACKGROUNDA recent clinical trial revealed that folic acid supplementation is associated with an increased incidence of prostate cancer (Figueiredo et al., J Natl Cancer Inst 2009; 101(6): 432–435). As tumor cells in culture proliferate directly in response to available folic acid, the goal of our study was to determine if there is a similar relationship between patient folate status, and the proliferative capacity of tumors in men with prostate cancer.METHODSSerum folate and/or prostate tissue folate was determined in 87 randomly selected patients undergoing surgery for prostate cancer, and compared to tumor proliferation in a subset.RESULTSFasting serum folate levels were positively correlated with prostate tumor tissue folate content (n = 15; r = 0.577, P < 0.03). Mean serum folate was 62.6 nM (7.5–145.2 nM), 39.5% of patients used supplements containing folic acid (n = 86). The top quartile of patients had serum folates above 82 nM, six times the level considered adequate. Of these, 48% reported no supplement use. Among 50 patients with Gleason 7 disease, the mean proliferation index as determined by Ki67 staining was 6.17 ± 3.2% and 0.86 ± 0.92% in the tumors from patients in the highest (117 ± 15 nM) and lowest (18 ± 9 nM) quintiles for serum folate, respectively (P < 0.0001).CONCLUSIONSIncreased cancer cell proliferation in men with higher serum folate concentrations is consistent with an increase in prostate cancer incidence observed with folate supplementation. Unexpectedly, more than 25% of patients had serum folate levels greater than sixfold adequate. Nearly half of these men reported no supplement use, suggesting either altered folate metabolism and/or sustained consumption of folic acid from fortified foods. Prostate 71:1287–1293, 2011. © 2011 Wiley‐Liss, Inc.
Biological properties of androgen receptor pure antagonist for treatment of castration‐resistant prostate cancer: Optimization from lead compound to CH5137291
Authors: Kawata Hiromitsu , Arai Shinichi , Nakagawa Toshito , Ishikura Nobuyuki , Nishimoto Ayako , Yoshino Hitoshi , Shiraishi Takuya , Tachibana Kazutaka , Nakamura Ryo , Sato Haruhiko 
Published: February 2011

AbstractBACKGROUNDCastration‐resistant prostate cancer (CRPC) is still dependent on androgen receptor (AR) signaling. We previously reported that a novel nonsteroidal AR pure antagonist, CH4933468, which is a thiohydantoin derivative with a sulfonamide side chain, provided in vitro proof of concept but did not in vivo.METHODSWe developed other derivatives, CH5137291, CH5138514, and CH5166623, and their pharmacological properties were compared with CH4933468 and bicalutamide. Agonist/antagonist activities in AR‐mediated transactivation, cell proliferation against LNCaP and LNCaP‐BC2, and AR translocation were evaluated. Agonist metabolite was monitored in liver microsomes and in pharmacokinetics experiments. Antitumor activities in CRPC xenograft models were examined using LNCaP‐BC2 and VCaP‐CRPC.RESULTSAll CH compounds completely inhibited AR‐mediated transactivation and proliferation of LNCaP and LNCaP‐BC2. In contrast bicalutamide showed a partial inhibition of AR‐mediated transactivation and a proliferation of LNCaP‐BC2. AR translocation to nucleus was inhibited by CH compounds, but stimulated by bicalutamide. In the LNCaP‐BC2 xenograft model, however, only CH5137291 showed significant inhibition of plasma PSA level and antitumor activity. The other three CH compounds were metabolized to their core structure which had agonist activity. CH5137291 also exhibited antitumor activity in a VCaP‐CRPC xenograft model, but bicalutamide did not.CONCLUSIONSThe molecular mechanism of the CH compounds, inhibition of AR translocation, was different from bicalutamide and this action could contribute to AR pure antagonist activity. Agonist metabolite diminished the antitumor activity of AR pure antagonist. CH5137291 exhibited antitumor activity in LNCaP‐BC2 and VCaP‐CRPC xenograft models, suggesting that the compound has potential for the treatment of CRPC. Prostate 71:1344–1356, 2011. © 2011 Wiley‐Liss, Inc.
SOCS‐3 antagonizes pro‐apoptotic effects of TRAIL and resveratrol in prostate cancer cells
Authors: Horndasch Manuela , Culig Zoran 
Published: February 2011

AbstractBACKGROUNDTherapy for advanced prostate cancer is only palliative and its improvement could be achieved by sensitization to pro‐apoptotic agents to which resveratrol belongs. We investigated the interaction between the tumor‐selective apoptosis inducer tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) and suppressor of cytokine signaling (SOCS‐3), an antiapoptotic molecule which is up‐regulated in prostate cancer.METHODSExpression of SOCS‐3 and TRAIL (death) receptors was determined by Western blot after treatment with TRAIL in prostate cancer cell lines. Binding of SOCS‐3 to death receptors was investigated by immunoprecipitation. Apoptosis rate was determined by a propidium iodide assay after treatment by TRAIL and resveratrol.RESULTSSOCS‐3, whose expression was differentially regulated by TRAIL in androgen‐insensitive prostate cell lines, binds to death receptor 4. Overexpression of SOCS‐3 reduced apoptosis in TRAIL‐ and resveratrol‐treated DU145 cells and SOCS‐3 siRNA increased apoptosis in TRAIL‐treated PC‐3 and LNCaP‐IL‐6+ cells.CONCLUSIONSOur results strongly suggest that SOCS‐3 is one of the proteins which influence the ability of TRAIL and resveratrol to cause programmed cell death in prostate cancer. Prostate 71:1357–1366, 2011. © 2011 Wiley‐Liss, Inc.
Associations between arachidonic acid metabolism gene polymorphisms and prostate cancer risk
Authors: Amirian E. Susan , Ittmann Michael M. , Scheurer Michael E. 
Published: February 2011

AbstractBACKGROUNDThe arachidonic acid (AA) pathway is suspected to be involved in the development of various cancers, including prostate cancer. However, the role of single nucleotide polymorphisms (SNPs) of AA pathway genes remains unclear. The purpose of this case–control study was to evaluate the association between prostate cancer risk and 14 such SNPs in the PTGS2, PTGES2, ALOX5, ALOX5AP, and LTA4H genes.METHODSGenotyping was conducted on 585 white prostate cancer cases and 585 healthy, age‐matched controls. The best genetic model for each SNP was determined using Akaike's information criterion. Odds ratios for the association between each SNP and prostate cancer risk were calculated, both overall and stratified by obesity (BMI ≥ 30). Haplotype analysis was conducted for the PTGES2 SNPs.RESULTSLTA4H rs1978331 was inversely associated with prostate cancer risk overall (unadjusted, overdominant model OR = 0.68, 95% CI: 0.51–0.91 for TC vs. TT/CC). Among non‐obese individuals, the GG genotype of PTGES2 rs10987883 was associated with an increased risk for prostate cancer (unadjusted, recessive model OR = 3.23, 95% CI: 1.27–8.23).CONCLUSIONSOur results indicate that SNPs in certain AA metabolism genes may influence prostate cancer susceptibility. Furthermore, it is possible that obesity, which induces a chronic state of low‐level inflammation in addition to several metabolic sequelae, may modify the impact of these SNPs. These findings should be confirmed in a larger study with power to detect differential effects by obesity. Prostate 71:1382–1389, 2011. © 2011 Wiley‐Liss, Inc.
Docetaxel‐mediated apoptosis in myeloid progenitor TF‐1 cells is mitigated by zinc: Potential implication for prostate cancer therapy
Authors: Makhov Peter , Kutikov Alexander , Golovine Konstantin , Uzzo Robert G. , Canter Daniel J. , Kolenko Vladimir M. 
Published: February 2011

AbstractBACKGROUNDDocetaxel‐based combination chemotherapy is approved by the FDA for the treatment of metastatic castration‐resistant prostate cancer. Unfortunately, docetaxel's efficacy is significantly limited by its considerable toxicity on hematopoietic progenitor cells, thus necessitating dose reduction or even discontinuation of the chemotherapy. Induction of pre‐mitotic arrest protects cells against docetaxel‐mediated toxicity and affords therapeutic opportunities.METHODSCell cycle progression was examined by propidium iodide staining. Zinc uptake was determined by FluoZin‐3 AM staining. Apoptotic DNA fragmentation was detected using APO‐BRDU kit.RESULTSIn the course of our current work, we treated the myeloid progenitor TF‐1 cells and the castration‐resistant PC‐3 and DU‐145 prostate cancer cells with physiologically relevant concentrations of zinc. In doing so, we were able to prevent docetaxel‐mediated mitotic arrest in zinc accumulating myeloid progenitor TF‐1 cells but not in castration‐resistant PC‐3 and DU‐145 prostate cancer cells. Moreover, pre‐treatment with zinc abolished docetaxel‐induced apoptosis in TF‐1 cells, whereas such treatment had no effect on apoptosis in PC‐3 and DU‐145 prostate cancer cells.CONCLUSIONSOur results suggest that zinc can protect myeloid progenitor cells against docetaxel‐induced toxicity without compromising the drug's anti‐tumor activity. Prostate 71:1413–1419, 2011. © 2011 Wiley‐Liss, Inc.
Toxicity of thiamethoxam to Tetranychus urticae Koch and Phytoseiulus persimilis Athias‐Henriot (Acari Tetranychidae, Phytoseiidae) through different routes of exposure
Authors: Pozzebon Alberto , Duso Carlo , Tirello Paola , Ortiz Paulina Bermudez 
Published: February 2011

AbstractBACKGROUND: Knowledge of the impact of insecticides on Tetranychus urticae Koch and its predator Phytoseiulus persimilis Athias‐Henriot is crucial for IPM. This study evaluates the effect of thiamethoxam on T. urticae and its predator by considering different routes of exposure (topical, residual and contaminated food exposures) and their combinations.RESULTS: Thiamethoxam effects on T. urticae were higher when residual and contaminated food exposures were considered. The total effect was higher than 90% where contaminated food exposure was involved. On P. persimilis, the total effect was higher in residual and contaminated prey exposures compared with topical exposure, and all combinations of routes of exposure attained a total effect higher than 90%.CONCLUSION: Thiamethoxam was found to be toxic to T. urticae and P. persimilis; however, the impact of the insecticide depended on the routes of exposure and their combinations. Lethal and sublethal effects occurred in residual and contaminated food exposures, while only sublethal effects occurred in topical exposure of predators and prey. The toxicity of thiamethoxam on prey and predator increased with the number of exposure routes involved. By limiting exposure to thiamethoxam to ingestion of contaminated food only, the impact of the pesticide was more favourable to P. persimilis than to its prey. Copyright © 2010 Society of Chemical Industry
Axorid: new NSAID formulation with built‐in GI protection
Authors: Norman Anthony , Hawkey Christopher 
Published: February 2011

AbstractAxorid is a new modifiedrelease combination of ketoprofen and omeprazole for patients with a previous history or at risk of NSAID‐associated GI ulceration. Here, Dr Anthony Norman and Professor Christopher Hawkey discuss its place in therapy. Copyright © 2011 Wiley Interface Ltd
Water chain encapsulated in carbon nanotube revealed by density functional theory
Authors: Wang Y. J. , Wang L. Y. 
Published: February 2011

AbstractThe noncovalent interactions between encapsulated water chains and single‐walled carbon nanotube (SWCNT) are studied using a self‐consistent charge density functional tight binding method with dispersion correction. The most interesting and important feature we observe is the diameter shrinking of CNTs when water chains are confined inside SWCNT. The diameter shrinking of CNTs can be suggested to the original of the van der Waals and H‐π interaction between water chains and CNTs. The calculated Raman spectra show the interactions between SWCNTs and water chains probably give rise to a kind of “mode hardening effect,” which agrees with the diameter shrinking of CNTs when water chains are confined inside SWCNT. © 2011 Wiley Periodicals, Inc. Int J Quantum Chem, 2011.